Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001193125-25-005004
Filing Date
2025-01-13
Accepted
2025-01-13 08:03:00
Documents
13
Period of Report
2025-01-13

Document Format Files

Seq Description Document Type Size
1 6-K d868096d6k.htm 6-K 28008
2 EX-4.1 d868096dex41.htm EX-4.1 85479
3 EX-4.2 d868096dex42.htm EX-4.2 91117
4 EX-4.3 d868096dex43.htm EX-4.3 91535
5 EX-4.4 d868096dex44.htm EX-4.4 17884
6 EX-5.1 d868096dex51.htm EX-5.1 63927
7 EX-5.2 d868096dex52.htm EX-5.2 11776
8 EX-10.1 d868096dex101.htm EX-10.1 193124
9 EX-10.2 d868096dex102.htm EX-10.2 52280
10 EX-99.1 d868096dex991.htm EX-99.1 10078
11 GRAPHIC g868096g0110115022617.jpg GRAPHIC 2739
12 GRAPHIC g868096g0110191410425.jpg GRAPHIC 3107
13 GRAPHIC g868096g0110191834336.jpg GRAPHIC 7125
  Complete submission text file 0001193125-25-005004.txt   664781
Mailing Address THREE INTERNATIONAL TOWERS LEVEL 24, 300 BARANGAROO AVENUE SYDNEY NSW C3 2000
Business Address THREE INTERNATIONAL TOWERS LEVEL 24, 300 BARANGAROO AVENUE SYDNEY NSW C3 2000 01161298780088
KAZIA THERAPEUTICS LTD (Filer) CIK: 0001075880 (see all company filings)

EIN.: 000000000 | State of Incorp.: C3 | Fiscal Year End: 0630
Type: 6-K | Act: 34 | File No.: 000-29962 | Film No.: 25524885
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)